Abstract By targeting treatment according to molecular biomarkers, precision medicine promises a revolution in healthcare. We examine this promise by distinguishing three precision medicine strategies: biomarker-stratified-high-risk-targeting, biomarker-based-individual-targeting, and biomarker-based-disease-targeting. Each strategy seeks to boost one of the determinants of the population impact of a medical intervention. We conclude that these strategies give a molecular coating to decades-old tactics. There is no compelling reason to believe that precision medicine strategies are uniquely effective for sick individuals or sick populations.
Chin‐Yee et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: